Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Extendicare ( (TSE:EXE) ).
Extendicare has announced the acquisition of CBI Home Health for $570 million, aiming to expand its home health care business and strengthen its national leadership position. This acquisition will diversify ParaMed’s geographic footprint, enhance its capabilities with innovative care models, and is expected to result in significant financial synergies and increased earnings per share, thereby delivering strong value for customers and shareholders.
The most recent analyst rating on (TSE:EXE) stock is a Buy with a C$17.50 price target. To see the full list of analyst forecasts on Extendicare stock, see the TSE:EXE Stock Forecast page.
Spark’s Take on TSE:EXE Stock
According to Spark, TipRanks’ AI Analyst, TSE:EXE is a Outperform.
Extendicare’s strong earnings call performance and positive technical indicators are the most significant factors driving the score. Financial performance is solid, though high leverage is a concern. Valuation is reasonable, and the dividend yield is attractive.
To see Spark’s full report on TSE:EXE stock, click here.
More about Extendicare
Extendicare is a company operating in the healthcare industry, primarily focusing on home health care services through its subsidiary, ParaMed Inc. The company aims to enhance its market presence and service offerings across Canada, particularly in Ontario and Alberta.
Average Trading Volume: 183,114
Technical Sentiment Signal: Buy
Current Market Cap: C$1.66B
See more data about EXE stock on TipRanks’ Stock Analysis page.